

How many pregnant women receive unnecessary anti-D prophylaxis?



Fetal Rhesus D Screening from Devyser Genomic Laboratories

Devyser Genomic Laboratories offers a proven, highly sensitive and accurate test¹ for non-invasive screening of fetal Rhesus D (RhD).

40% of Rh-negative mothers are carrying an Rh-negative fetus and would be exposed to unnecessary treatment with potential risks.²

With our test results, physicians can ensure that only mothers that need anti-D prophylaxis, receive it.

Personalized treatment


Empowers patients to decide on the testing and treatment they want during pregnancy.

Non-invasive


Sample collection from gestation week 10 and a single EDTA blood tube is all that is needed.

Saves time


Avoid multiple visits to the care provider for injections.



Non-invasive
blood draw



Rhesus D test



Reduce
unnecessary
prophylaxis

1. Laboratory-developed test

2. de Haas M, Finning K, Massey E, Roberts DJ. Anti-D prophylaxis: past, present and future. *Transfus Med.* 2014;24(1):1-7. doi:10.1111/tme.12099

Dvysr[®]

Devyser – a new level of certainty


   @Devyser

www.devyser.com



State-of-the-art fetal Rhesus D test

Our Rhesus D service process



Contact [**order@us.devysr.com**](mailto:order@us.devysr.com) to order

Devysr®

Devysr – a new level of certainty

Devysr Genomic Laboratories

11660 Alpharetta Highway
Suite 700, Office 790
Roswell, GA 30076

ClientServices@us.devysr.com

www.devysr.com